Regulatory Information
HSA regulatory responsibility and product classification details
Regulatory Responsibility
Product Classification
Formulation Information
INJECTION, POWDER, FOR SOLUTION
**4.2 Posology and method of administration** Posology - _Therapeutic indication (Severe hypoglycaemia)_ Dosage for adult patients: Administer 1 mg by subcutaneous or intramuscular injection. Special populations _Paediatric population (< 18 years old):_ GlucaGen® can be used for the treatment of severe hypoglycaemia in children and adolescents. Dosage for paediatric patients: Administer 0.5 mg (children below 25 kg or younger than 8 years) or 1 mg (children above 25 kg or older than 8 years). _Elderly (≥ 65 years old):_ GlucaGen® can be used in elderly patients. _Renal and hepatic impairment:_ GlucaGen® can be used in patients with renal and hepatic impairment. - _Diagnostic indication (Inhibition of gastrointestinal motility)_ Dosage for adult patients: The diagnostic dose for relaxation of the stomach, duodenal bulb, duodenum and small bowel is 0.2–0.5 mg given as intravenous injection or 1 mg given intramuscularly; the dose to relax the colon is 0.5–0.75 mg intravenously or 1–2 mg intramuscularly. Special populations _Paediatric population (< 18 years old):_ The safety and efficacy of GlucaGen® for inhibition of gastrointestinal motility in children and adolescents have not been established. No data are available. _Elderly (≥ 65 years old):_ GlucaGen® can be used in elderly patients. _Renal and hepatic impairment:_ GlucaGen® can be used in patients with renal and hepatic impairment. Method of administration Dissolve the compacted powder in the accompanying solvent, as described in section 6.6 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information._ _Therapeutic indication (Severe hypoglycaemia):_ Administer by subcutaneous or intramuscular injection. The patient will normally respond within 10 minutes. When the patient has responded to the treatment, give oral carbohydrates to restore the liver glycogen and prevent relapse of hypoglycaemia. If the patient does not respond within 10 minutes, intravenous glucose should be given. _Diagnostic indication (Inhibition of gastrointestinal motility):_ GlucaGen® must be administered by medical personnel. Onset of action after an intravenous injection of 0.2–0.5 mg occurs within one minute and the duration of effect is between 5 and 20 minutes. The onset of action after an intramuscular injection of 1–2 mg occurs after 5–15 minutes and lasts approximately 10–40 minutes. After the end of the diagnostic procedure, oral carbohydrates should be given, if this is compatible with the diagnostic procedure applied.
INTRAVENOUS, SUBCUTANEOUS, INTRAMUSCULAR
Medical Information
**4.1 Indications** Therapeutic indication GlucaGen® is indicated for treatment of severe hypoglycaemic reactions, which may occur in the management of insulin treated children and adults with diabetes mellitus. Diagnostic indication GlucaGen® is indicated for motility inhibition in examinations of the gastrointestinal tract in adults.
**4.3 Contraindications** Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_. Pheochromocytoma.
H04AA01
glucagon
Manufacturer Information
NOVO NORDISK PHARMA (SINGAPORE) PTE LTD
Novo Nordisk A/S
Novo Nordisk A/ S
Active Ingredients
Documents
Package Inserts
Glucagen For Injection PI.pdf
Approved: October 22, 2020